Analyst Price Targets — ACRS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 1, 2026 10:21 am | Edward Nash | Canaccord Genuity | $10.00 | $6.05 | TheFly | Aclaris Therapeutics initiated with a Buy at Canaccord |
| May 5, 2026 10:53 am | Biren Amin | Piper Sandler | $11.00 | $4.53 | TheFly | Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler |
| May 5, 2026 8:29 am | — | Guggenheim | $12.00 | $4.53 | TheFly | Aclaris Therapeutics initiated with a Buy at Guggenheim |
| April 29, 2026 11:44 am | Martin Fan | Wedbush | $10.00 | $4.22 | TheFly | Aclaris Therapeutics price target raised to $10 from $8 at Wedbush |
| April 16, 2026 10:44 am | — | UBS | $10.00 | $3.93 | TheFly | Aclaris Therapeutics initiated with an Outperform at Oppenheimer |
| January 30, 2026 12:09 pm | Adam Vogel | Craig-Hallum | $10.00 | $3.43 | TheFly | Craig-Hallum bullish on Aclaris Therapeutics, initiates with a Buy |
| November 19, 2024 7:35 am | Julian Harrison | BTIG | $8.00 | $3.14 | StreetInsider | BTIG Upgrades Aclaris Therapeutis (ACRS) to Buy |
| November 19, 2024 7:34 am | Roger Song | Jefferies | $7.00 | $3.14 | StreetInsider | Jefferies Upgrades Aclaris Therapeutis (ACRS) to Buy |
| November 6, 2024 5:46 pm | Alex Thompson | Stifel Nicolaus | $3.00 | $2.28 | StreetInsider | Aclaris Therapeutis (ACRS) PT Raised to $3 at Stifel |
| December 1, 2022 5:35 am | — | Goldman Sachs | $25.00 | $15.22 | Benzinga | Goldman Sachs Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $25 |
Latest News for ACRS
Deutsche Bank AG purchased a new stake in Aclaris Therapeutics, Inc. (NASDAQ: ACRS) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,040,955 shares of the biotechnology company's stock, valued at approximately $5,507,000. Deutsche Bank AG owned about 0.75% of
The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation for modzatinib (ATI-2138) for moderate to severe lichen planus (LP) including oral erosive LP,…
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.13 per share a year ago.
- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Timelines Reaffirmed for Upcoming Top Line Results from Phase 1b Proof-of-Concept (POC) Trials of ATI-052 and Phase 2 Trial of Bosakitug (ATI-045) - - Strong Cash Runway Expected to Enable Development of Pipeline Through the End of 2028 - WAYNE, Pa., Aug. 06, 2026…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ACRS.
U.S. House Trading
No House trades found for ACRS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.